Frenova Empowers Investigators and Research Teams
Why Frenova? As a Fresenius Medical Care company, Frenova manages the world’s largest network of renal research assets: over 550…
Protocol Design Trends Investigators Should Look for When Selecting Studies
For investigative sites, selecting studies for increased patient centricity, whether through decentralized trials, patient input in study design, or remote…
Building a Global Research Network: Chronic Kidney Disease as a Public Health Crisis
At least 20% of people aged 65 to 74, and 50% of people over 75, have chronic kidney disease. However,…
Missed Revenue in Clinical Research: 1 Study, 10 Sites, $154,000 Caught
Whether from faulty sponsor payment systems, incomplete invoicing, or other causes, private practice investigational sites routinely miss out on significant…
Start with the Patient in Mind – Interview With Patient Partner Donnie King
Start with the patient in mind — let’s renew our resolve to represent those who participate in studies to advance…
Overcoming Barriers to Enrolling Renal Patients in Clinical Trials: Q&A With Kurt Mussina
Kurt Mussina, General Manager of Frenova Renal Research and Vice President of Clinical Studies Operations for Fresenius Medical Care North…
F1RST Up®: Accelerating Clinical Trial Start-Up
Despite the pressing need to bring novel therapies to patients with renal impairments, the development time and cost to bring…
Prevent the Real World From Derailing Your Clinical Trial: Focus On Protocol Design
Clinical trial sponsors are continually seeking ways to improve the speed and efficiency of their clinical development projects. However, they…
Starting With The Patient In Mind
In our desire for efficiency, it’s easy to forget that the patient care we provide during a clinical trial isn’t…
Chronic Kidney Disease in Primary Care: Outcomes after Five Years in a Prospective Cohort Study
Chronic kidney disease (CKD) is commonly managed in primary care, but most guidelines have a secondary care perspective emphasizing the…